# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ProPhase Labs (NASDAQ:PRPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.18)...
Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug ...
ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagn...
ProPhase Labs (NASDAQ:PRPH) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.2...
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly loss at $0.10 per share on re...
HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $11 price target.
ProPhase Labs, Inc. (NASDAQ:PRPH), a next generation biotech, genomics and diagnostics company, today announced important devel...